211 related articles for article (PubMed ID: 36271358)
1. The protein aggregation inhibitor YAT2150 has potent antimalarial activity in Plasmodium falciparum in vitro cultures.
Bouzón-Arnáiz I; Avalos-Padilla Y; Biosca A; Caño-Prades O; Román-Álamo L; Valle J; Andreu D; Moita D; Prudêncio M; Arce EM; Muñoz-Torrero D; Fernàndez-Busquets X
BMC Biol; 2022 Oct; 20(1):197. PubMed ID: 36271358
[TBL] [Abstract][Full Text] [Related]
2. Activity of Ivermectin and Its Metabolites against Asexual Blood Stage Plasmodium falciparum and Its Interactions with Antimalarial Drugs.
Yipsirimetee A; Tipthara P; Hanboonkunupakarn B; Tripura R; Lek D; Kümpornsin K; Lee MCS; Sattabongkot J; Dondorp AM; White NJ; Kobylinski KC; Tarning J; Chotivanich K
Antimicrob Agents Chemother; 2023 Jul; 67(7):e0173022. PubMed ID: 37338381
[TBL] [Abstract][Full Text] [Related]
3. Blood-stage antiplasmodial activity and oocyst formation-blockage of metallo copper-cinchonine complex.
Morais CMG; Brito RMM; Weselucha-Birczyńska A; Pereira VSS; Pereira-Silva JW; Menezes A; Pessoa FAC; Kucharska M; Birczyńska-Zych M; Ríos-Velásquez CM; de Andrade-Neto VF
Front Cell Infect Microbiol; 2022; 12():1047269. PubMed ID: 36530433
[TBL] [Abstract][Full Text] [Related]
4. Development of Mitochondria Targeting AIE-Active Cyclometalated Iridium Complexes as Potent Antimalarial Agents.
Kumari G; Gupta A; Sah RK; Gautam A; Saini M; Gupta A; Kushawaha AK; Singh S; Sasmal PK
Adv Healthc Mater; 2023 Apr; 12(9):e2202411. PubMed ID: 36515128
[TBL] [Abstract][Full Text] [Related]
5. On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity.
Edgar RCS; Malcolm TR; Siddiqui G; Giannangelo C; Counihan NA; Challis M; Duffy S; Chowdhury M; Marfurt J; Dans M; Wirjanata G; Noviyanti R; Daware K; Suraweera CD; Price RN; Wittlin S; Avery VM; Drinkwater N; Charman SA; Creek DJ; de Koning-Ward TF; Scammells PJ; McGowan S
mBio; 2024 Jun; 15(6):e0096624. PubMed ID: 38717141
[TBL] [Abstract][Full Text] [Related]
6. Dinuclear and mononuclear metal(II) polypyridyl complexes against drug-sensitive and drug-resistant Plasmodium falciparum and their mode of action.
Lai JW; Maah MJ; Tan KW; Sarip R; Lim YAL; Ganguly R; Khaw LT; Ng CH
Malar J; 2022 Dec; 21(1):386. PubMed ID: 36528584
[TBL] [Abstract][Full Text] [Related]
7. Effect of the aggregated protein dye YAT2150 on
Román-Álamo L; Avalos-Padilla Y; Bouzón-Arnáiz I; Iglesias V; Fernández-Lajo J; Monteiro JM; Rivas L; Fisa R; Riera C; Andreu D; Pintado-Grima C; Ventura S; Arce EM; Muñoz-Torrero D; Fernàndez-Busquets X
Antimicrob Agents Chemother; 2024 Mar; 68(3):e0112723. PubMed ID: 38349159
[TBL] [Abstract][Full Text] [Related]
8. Tartrolon E, a secondary metabolite of a marine symbiotic bacterium, is a potent inhibitor of asexual and sexual
Chery-Karschney L; Patrapuvich R; Mudeppa DG; Kokkonda S; Chakrabarti R; Sriwichai P; O'Connor RM; Rathod PK; White J
Antimicrob Agents Chemother; 2024 Feb; 68(2):e0068423. PubMed ID: 38193705
[TBL] [Abstract][Full Text] [Related]
9. Targeting malaria parasites with novel derivatives of azithromycin.
Burns AL; Sleebs BE; Gancheva M; McLean KT; Siddiqui G; Venter H; Beeson JG; O'Handley R; Creek DJ; Ma S; Frölich S; Goodman CD; McFadden GI; Wilson DW
Front Cell Infect Microbiol; 2022; 12():1063407. PubMed ID: 36530422
[TBL] [Abstract][Full Text] [Related]
10. High Target Homology Does Not Guarantee Inhibition: Aminothiazoles Emerge as Inhibitors of
Johannsen S; Gierse RM; Krüger A; Edwards RL; Nanna V; Fontana A; Zhu D; Masini T; de Carvalho LP; Poizat M; Kieftenbelt B; Hodge DM; Alvarez S; Bunt D; Lacour A; Shams A; Meissner KA; de Souza EE; Dröge M; van Vliet B; den Hartog J; Hutter MC; Held J; Odom John AR; Wrenger C; Hirsch AKH
ACS Infect Dis; 2024 Mar; 10(3):1000-1022. PubMed ID: 38367280
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Plasmodium falciparum prohibitins as novel targets to block infection in humans by impairing the growth and transmission of the parasite.
Saini M; Ngwa CJ; Marothia M; Verma P; Ahmad S; Kumari J; Anand S; Vandana V; Goyal B; Chakraborti S; Pandey KC; Garg S; Pati S; Ranganathan A; Pradel G; Singh S
Biochem Pharmacol; 2023 Jun; 212():115567. PubMed ID: 37088154
[TBL] [Abstract][Full Text] [Related]
12. Mitigating the risk of antimalarial resistance via covalent dual-subunit inhibition of the Plasmodium proteasome.
Deni I; Stokes BH; Ward KE; Fairhurst KJ; Pasaje CFA; Yeo T; Akbar S; Park H; Muir R; Bick DS; Zhan W; Zhang H; Liu YJ; Ng CL; Kirkman LA; Almaliti J; Gould AE; Duffey M; O'Donoghue AJ; Uhlemann AC; Niles JC; da Fonseca PCA; Gerwick WH; Lin G; Bogyo M; Fidock DA
Cell Chem Biol; 2023 May; 30(5):470-485.e6. PubMed ID: 36963402
[TBL] [Abstract][Full Text] [Related]
13. Plasmodium falciparum ring-stage plasticity and drug resistance.
Platon L; Ménard D
Trends Parasitol; 2024 Feb; 40(2):118-130. PubMed ID: 38104024
[TBL] [Abstract][Full Text] [Related]
14. Effects of the G-quadruplex-binding drugs quarfloxin and CX-5461 on the malaria parasite Plasmodium falciparum.
Craven HM; Nettesheim G; Cicuta P; Blagborough AM; Merrick CJ
Int J Parasitol Drugs Drug Resist; 2023 Dec; 23():106-119. PubMed ID: 38041930
[TBL] [Abstract][Full Text] [Related]
15. Bridging the Gap in Malaria Parasite Resistance, Current Interventions, and the Way Forward from in Silico Perspective: A Review.
Kumi RO; Oti B; Abo-Dya NE; Alahmdi MI; Soliman MES
Molecules; 2022 Nov; 27(22):. PubMed ID: 36432016
[TBL] [Abstract][Full Text] [Related]
16. Methods Used to Investigate the
Edgar RCS; Counihan NA; McGowan S; de Koning-Ward TF
Front Cell Infect Microbiol; 2021; 11():829823. PubMed ID: 35096663
[No Abstract] [Full Text] [Related]
17.
Dobrescu I; Hammam E; Dziekan JM; Claës A; Halby L; Preiser P; Bozdech Z; Arimondo PB; Scherf A; Nardella F
ACS Infect Dis; 2023 Jun; 9(6):1257-1266. PubMed ID: 37216290
[TBL] [Abstract][Full Text] [Related]
18. Identification of covalent fragment inhibitors for Plasmodium falciparum UCHL3 with anti-malarial efficacy.
Imhoff RD; Rosenthal MR; Ashraf K; Bhanot P; Ng CL; Flaherty DP
Bioorg Med Chem Lett; 2023 Oct; 94():129458. PubMed ID: 37634761
[TBL] [Abstract][Full Text] [Related]
19. Potent acyl-CoA synthetase 10 inhibitors kill Plasmodium falciparum by disrupting triglyceride formation.
Bopp S; Pasaje CFA; Summers RL; Magistrado-Coxen P; Schindler KA; Corpas-Lopez V; Yeo T; Mok S; Dey S; Smick S; Nasamu AS; Demas AR; Milne R; Wiedemar N; Corey V; Gomez-Lorenzo MG; Franco V; Early AM; Lukens AK; Milner D; Furtado J; Gamo FJ; Winzeler EA; Volkman SK; Duffey M; Laleu B; Fidock DA; Wyllie S; Niles JC; Wirth DF
Nat Commun; 2023 Mar; 14(1):1455. PubMed ID: 36927839
[TBL] [Abstract][Full Text] [Related]
20. Discovery of potent Plasmodium falciparum protein kinase 6 (PfPK6) inhibitors with a type II inhibitor pharmacophore.
Ong HW; Truong A; Kwarcinski F; de Silva C; Avalani K; Havener TM; Chirgwin M; Galal KA; Willis C; Krämer A; Liu S; Knapp S; Derbyshire ER; Zutshi R; Drewry DH
Eur J Med Chem; 2023 Mar; 249():115043. PubMed ID: 36736152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
